Contact UsInvestorsCareersMediaScienceContact Us
HomePartnershipsWorking with the NHS and other Healthcare OrganisationsDonations and GrantsIndependent Medical Grants and DonationsSupporting the integration of NHS ICS headache pathways for better patient outcomesSupporting the integration of NHS ICS headache pathways for better patient outcomesPfizer is now inviting applications from UK health organisations, for a competitive Quality Improvement Grant, that will fund quality improvement initiatives focused on NHS Integrated Care Services Headache Pathways.

The grant application closing date will be 25th June 2024 at 23:59 BST. The anticipated grant award notification will be September 2024 and grants will be distributed following a fully executed agreement and submission of Final Protocol, documentation of IRB/IEC approval, regulatory approval (if applicable), exemption or waiver.

Please note that Pfizer is unable to accept applications with a start date earlier than September 2024 since full execution of the Grant Agreement must occur prior to the Project Start Date. Projects must have a maximum duration of 12 months.

Existing best practice pathways that have an educational component only will be considered for funding up to £10,000. Individual projects that propose the implementation of an integrated headache pathway will be considered for funding up to £20,000. Only projects that have exceptional potential patient reach using innovative ideas may be considered above these ranges. Please apply in Great British Pounds (GBP).

The estimated total available budget related to this request for proposal (RFP) is £102,000 GBP.
 

The NHS integrated care services headache pathways for better patient outcomes that incorporate GIRFT (Getting It Right First Time) neurology report recommendations, outlined in The Further Faster Programme/ Clinically led Specialty Outpatient Guidance and NNAG (National Neurosciences Advisory Group) pathway will be considered for Pfizer grant support. These may include but not be limited to:

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement programme.

Only organisations (e.g. NHS trusts/departments or professional organisations/charities such as Royal Colleges) are eligible to receive grants, not individuals or medical practice groups. If the project involves multiple departments within an institution and/or between different institutions / organisations / associations. All institutions must have a relevant role and the requesting organisation must have a key role in the project. The applicant must be the Project Lead/Principal Investigator (PI) or an authorised designee of such individual (e.g., Project Lead/PI’s grant/research coordinator). The Project Lead/PI must be an employee or independent contractor of the requesting organisation.

The requesting organisation must be legally able to receive award funding directly from Pfizer International LLC, a United States based entity. We strongly recommend that applicants confirm this with their organisation or institution prior to submitting an application. Grants awarded to organisations that are subsequently found to be unable to accept funding directly from Pfizer International LLC, a United States based entity, may be subject to rescission.

Click here for full details of the scope of the RFP and how to apply

Please follow the steps below on how to apply for the Pfizer Quality Improvement RFP:

In the application:

Requirements for submission:

IMPORTANT: Please be advised applications submitted after the due date will not be reviewed.

Pfizer’s GMG competitive grant programme involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an Internal Review Panel (IRP) to make final grant decisions. Organisations are invited to submit an application addressing the specific gaps in practice as outlined in the specific RFP.

To contact Pfizer for any other purpose, including adverse event reporting, medical information requests, or data protection enquiries please call 01304 616161.

PP-UNP-GBR-8812 / April 2024
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.